Atossa Highlights Emerging Opportunity for (Z)-Endoxifen in Duchenne Muscular Dystrophy, Including Symptomatic Female Carriers, Following Peer-Reviewed Publication and Scientific Presentat...
Atossa Therapeutics, Inc. (ATOS)
Last atossa therapeutics, inc. earnings: 11/13 04:10 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.atossagenetics.com
Company Research
Source: Yahoo! Finance
scientific presentation to spotlight potential in Duchenne carrier–associated pathologies SEATTLE Nov. 17, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines in oncology, announces a growing body of scientific work supporting the potential role of its investigational therapy (Z)-endoxifen in DMD, a severe, progressive, and ultimately fatal neuromuscular disease, in addition to Duchenne carrier–associated pathologies (D-CAPs) that affect a subset of female carriers. The momentum is anchored by a newly published, peer-reviewed hypothesis article and an upcoming invited scientific presentation. Where innovation meets purpose. Dedicated to transforming breast cancer care with breakthrough science and patient-centric solutions (PRNewsfoto/Atossa Therapeutics Inc) Newly published hypothesis article outlines why (Z)-endoxifen may matter in DMD The article about (Z)-Endoxif
Show less
Read more
Impact Snapshot
Event Time:
ATOS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATOS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATOS alerts
High impacting Atossa Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ATOS
News
- Atossa Therapeutics Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across Breast Cancer ContinuumPR Newswire
- Insilico Medicine and Atossa Therapeutics Publish AI-Driven Study in Nature Scientific Reports Identifying (Z)-Endoxifen as a Potential Therapeutic Candidate for GlioblastomaPR Newswire
- Atossa Highlights Emerging Opportunity for (Z)-Endoxifen in Duchenne Muscular Dystrophy, Including Symptomatic Female Carriers, Following Peer-Reviewed Publication and Scientific PresentationPR Newswire
- Atossa Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update [Yahoo! Finance]Yahoo! Finance
- Atossa Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate UpdatePR Newswire
ATOS
Analyst Actions
- 9/22/25 - Ascendiant Capital
ATOS
Sec Filings
- 12/4/25 - Form 8-K
- 11/12/25 - Form 10-Q
- 11/12/25 - Form 8-K
- ATOS's page on the SEC website